药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Gancotamab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Gancotamab.
Tiludronic acid
Setrusumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Setrusumab.
Tiludronic acid
Camrelizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Camrelizumab.
Tiludronic acid
Risankizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Risankizumab.
Tiludronic acid
Emapalumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emapalumab.
Tiludronic acid
Cemiplimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cemiplimab.
Tiludronic acid
Lanadelumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lanadelumab.
Tiludronic acid
Lecanemab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lecanemab.
Tiludronic acid
Fanolesomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fanolesomab.
Tiludronic acid
Galcanezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Galcanezumab.
Tiludronic acid
Fremanezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fremanezumab.
Tiludronic acid
Eptinezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eptinezumab.
Tiludronic acid
Erenumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Erenumab.
Tiludronic acid
Burosumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Burosumab.
Tiludronic acid
Tildrakizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tildrakizumab.
Tiludronic acid
Besilesomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Besilesomab.
Tiludronic acid
Sulesomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sulesomab.
Tiludronic acid
Emicizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emicizumab.
Tiludronic acid
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human cytomegalovirus immune globulin.
Tiludronic acid
Nebacumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nebacumab.